These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29856158)

  • 21. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.
    Zhao S; Yan X; Ding J; Ren K; Sun S; Lu J; Zhang C; Zhang K; Li Z; Guo J
    Front Neurol; 2022; 13():857402. PubMed ID: 35547386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
    Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
    Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low conversion rate of ocular to generalized myasthenia gravis in Singapore.
    Teo KY; Tow SL; Haaland B; Gosavi TD; Jing-Liang L; Yew Long LO; Milea D
    Muscle Nerve; 2018 May; 57(5):756-760. PubMed ID: 28981152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular Myasthenia Gravis: A Current Overview.
    Behbehani R
    Eye Brain; 2023; 15():1-13. PubMed ID: 36778719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis.
    Kemchoknatee P; Arepagorn A; Srisombut T
    Asian Pac J Allergy Immunol; 2021 Oct; ():. PubMed ID: 34717528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new mouse model of autoimmune ocular myasthenia gravis.
    Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody profile may predict outcome in ocular myasthenia gravis.
    Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
    Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of electrodiagnostic tests in ocular myasthenia gravis.
    Katzberg HD; Bril V
    J Clin Neuromuscul Dis; 2005 Mar; 6(3):109-13. PubMed ID: 19078758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular myasthenia gravis: an update on diagnosis and treatment.
    Fortin E; Cestari DM; Weinberg DH
    Curr Opin Ophthalmol; 2018 Nov; 29(6):477-484. PubMed ID: 30281029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
    Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
    Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
    Deng Y; Zhang X
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease.
    Claytor B; Li Y
    Muscle Nerve; 2021 May; 63(5):631-639. PubMed ID: 33247453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single fiber electromyography in the diagnosis of ocular myasthenia gravis: report of 90 cases.
    Cui LY; Guan YZ; Wang H; Tang XF
    Chin Med J (Engl); 2004 Jun; 117(6):848-51. PubMed ID: 15198885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
    Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
    Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative modifications of blood serum proteins in myasthenia gravis.
    Adamczyk-Sowa M; Bieszczad-Bedrejczuk E; Galiniak S; Rozmiłowska I; Czyżewski D; Bartosz G; Sadowska-Bartosz I
    J Neuroimmunol; 2017 Apr; 305():145-153. PubMed ID: 28284335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric Ocular Myasthenia Gravis.
    Fisher K; Shah V
    Curr Treat Options Neurol; 2019 Sep; 21(10):46. PubMed ID: 31559492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversies in Ocular Myasthenia Gravis.
    Evoli A; Iorio R
    Front Neurol; 2020; 11():605902. PubMed ID: 33329368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population.
    Somnier FE; Trojaborg W
    Electroencephalogr Clin Neurophysiol; 1993 Apr; 89(2):73-87. PubMed ID: 7683605
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.